The protracted natural history and lack of curative therapy for advanced prostate cancer makes complementary and alternative medicine (CAM) attractive to patients.
CAM is as widely practiced as traditional medicine.
Antioxidant and hormonal influences of dietary and alternative therapies hold promise for the prevention and treatment of prostate cancer.
The lack of quality control of CAMs that are offered as dietary supplements makes them susceptible to adulteration.
New models for how to incorporate studies of CAM into chemoprevention and therapeutic trials are badly needed.
Complementary and alternative medicine (CAM) encompasses a wide range of interventions that are often used for the prevention and treatment of malignant disease. As prostate cancer is characterized by strong dietary influences, a long disease latency period and limited treatment strategies for advanced disease, many patients turn to CAM with the belief that they represent a viable therapeutic option that is free of adverse side effects. Although the efficacy of many CAM therapies seems compelling, definitive studies are underway and the potentially harmful effects of these 'natural' interventions need to be recognized.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jemal, A. et al. Cancer statistics, 2003. CA Cancer J. Clin. 53, 5–26 (2003).
Engel, L. W. & Straus, S. E. Development of therapeutics: opportunities within complementary and alternative medicine. Nature Rev. Drug Discov. 1, 229–237 (2002).
Eisenberg, D. M. et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280, 1569–1575 (1998).
Eisenberg, D. M. et al. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N. Engl. J. Med. 328, 246–252 (1993). A landmark study that documents the extent and patterns of CAM use in the United States.
Jones, H. A., Metz, J. M., Devine, P., Hahn, S. M. & Whittington, R. Rates of unconventional medical therapy use in patients with prostate cancer: standard history versus directed questions. Urology 59, 272–276 (2002).
Kelloff, G. J. et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J. Nutr. 130, 467S–471S (2000).
Fletcher, R. H. & Fairfield, K. M. Vitamins for chronic disease prevention in adults: clinical applications. JAMA 287, 3127–3129 (2002).
Nam, R. K. et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J. Urol. 161, 1521–1524 (1999).
Zhang, X. K. Vitamin A and apoptosis in prostate cancer. Endocr. Relat. Cancer 9, 87–102 (2002).
Rohan, T. E., Howe, G. R., Burch, J. D. & Jain, M. Dietary factors and risk of prostate cancer: a case–control study in Ontario, Canada. Cancer Causes Control 6, 145–154 (1995).
Schuurman, A. G., Goldbohm, R. A., Brants, H. A. & van den Brandt, P. A. A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). Cancer Causes Control 13, 573–582 (2002).
Dawson, M. I. The importance of vitamin A in nutrition. Curr. Pharm. Des. 6, 311–325 (2000).
Jamison, J. M., Gilloteaux, J., Taper, H. S. & Summers, J. L. Evaluation of the in vitro and in vivo antitumor activities of vitamin C and K-3 combinations against human prostate cancer. J. Nutr. 131, 158S–160S (2001).
Daviglus, M. L. et al. Dietary β-carotene, vitamin C, and risk of prostate cancer: results from the Western Electric Study. Epidemiology 7, 472–427 (1996).
Willis, M. S. & Wians, F. H. The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of action of various dietary substances. Clin. Chim. Acta 330, 57–83 (2003).
Kristal, A. R., Stanford, J. L., Cohen, J. H., Wicklund, K. & Patterson, R. E. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 8, 887–892 (1999).
Miller, G. J. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev. 17, 353–360 (1998).
Schwartz, G. G. & Hulka, B. S. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res. 10, 1307–1311 (1990).
Schwartz, G. G., Hill, C. C., Oeler, T. A., Becich, M. J. & Bahnson, R. R. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 46, 365–369 (1995).
Lokeshwar, B. L. et al. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol. Biomarkers Prev. 8, 241–248 (1999).
Beer, T. M. et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol. 21, 123–128 (2003).
Chan, J. M. & Giovannucci, E. L. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol. Rev. 23, 87–92 (2001).
Jiang, Q., Christen, S., Shigenaga, M. K. & Ames, B. N. γ-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am. J. Clin. Nutr. 74, 714–722 (2001).
Sigounas, G., Anagnostou, A. & Steiner, M. dl-α-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr. Cancer 28, 30–35 (1997).
Zhang, Y. et al. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc. Natl Acad. Sci. USA 99, 7408–7413 (2002).
Vlajinac, H. D., Marinkovic, J. M., Ilic, M. D. & Kocev, N. I. Diet and prostate cancer: a case–control study. Eur. J. Cancer 33, 101–107 (1997).
Deneo-Pellegrini, H., De Stefani, E., Ronco, A. & Mendilaharsu, M. Foods, nutrients and prostate cancer: a case–control study in Uruguay. Br. J. Cancer 80, 591–597 (1999).
Tzonou, A. et al. Diet and cancer of the prostate: a case–control study in Greece. Int. J. Cancer 80, 704–708 (1999).
Heinonen, O. P. et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J. Natl Cancer Inst. 90, 440–446 (1998).
Moyad, M. A. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology 59, 9–19 (2002).
Gann, P. H. et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 59, 1225–1230 (1999). Epidemiological study that indicates a role for lycopene in preventing prostate cancer.
Chan, J. M. et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol. Biomarkers Prev. 8, 893–899 (1999).
Liede, K. E., Haukka, J. K., Saxen, L. M. & Heinonen, O. P. Increased tendency towards gingival bleeding caused by joint effect of α-tocopherol supplementation and acetylsalicylic acid. Ann. Med. 30, 542–546 (1998).
Klein, E. A. et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J. Urol. 166, 1311–1315 (2001).
Combs, G. F. Jr & Combs, S. B. The nutritional biochemistry of selenium. Annu. Rev. Nutr. 4, 257–280 (1984).
Clark, L. C. et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957–1963 (1996). Randomized study of selenium supplementation that suppressed the development of prostate cancer.
Menter, D. G., Sabichi, A. L. & Lippman, S. M. Selenium effects on prostate cell growth. Cancer Epidemiol. Biomarkers Prev. 9, 1171–1182 (2000).
Platz, E. A. & Helzlsouer, K. J. Selenium, zinc, and prostate cancer. Epidemiol. Rev. 23, 93–101 (2001).
Griffin, A. C. Role of selenium in the chemoprevention of cancer. Adv. Cancer Res. 29, 419–442 (1979).
Dong, Y., Zhang, H., Hawthorn, L., Ganther, H. E. & Ip, C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res. 63, 52–59 (2003).
Duffield-Lillico, A. J. et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev. 11, 630–9 (2002).
Vinceti, M., Wei, E. T., Malagoli, C., Bergomi, M. & Vivoli, G. Adverse health effects of selenium in humans. Rev. Environ. Health 16, 233–251 (2001).
Giovannucci, E. et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res. 58, 442–447 (1998).
Berndt, S. I. et al. Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 60, 1118–1123 (2002).
Jain, M. G., Hislop, G. T., Howe, G. R., Burch, J. D. & Ghadirian, P. Alcohol and other beverage use and prostate cancer risk among Canadian men. Int. J. Cancer 78, 707–711 (1998).
Gupta, S., Hussain, T. & Mukhtar, H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem. Biophys. 410, 177–185 (2003).
Garbisa, S. et al. Tumor invasion: molecular shears blunted by green tea. Nature Med. 5, 1216 (1999).
Gupta, S., Hastak, K., Ahmad, N., Lewin, J. S. & Mukhtar, H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl Acad. Sci. USA 98, 10350–10355 (2001).
Zhou, J. R., Yu, L., Zhong, Y. & Blackburn, G. L. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J. Nutr. 133, 516–521 (2003).
Pisters, K. M. et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J. Clin. Oncol. 19, 1830–1838 (2001).
Jatoi, A. et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97, 1442–1446 (2003).
Evans, B. A., Griffiths, K. & Morton, M. S. Inhibition of 5 α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J. Endocrinol. 147, 295–302 (1995).
Markovits, J. et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49, 5111–5117 (1989).
Mentor-Marcel, R., Lamartiniere, C. A., Eltoum, I. E., Greenberg, N. M. & Elgavish, A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 61, 6777–6782 (2001).
Trevedi, C. Modulation in prostate cancer (PCA) patients (Pts) by soy isoflavones (SI). Am. Soc. Clin. Oncol. A1363 (2000).
Pidgeon, G. P., Kandouz, M., Meram, A. & Honn, K. V. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 62, 2721–2727 (2002).
Chen, S. et al. Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif. 34, 293–304 (2001).
Timar, J. et al. Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int. J. Cancer 87, 37–43 (2000).
Ye, F., Xui, L., Yi, J., Zhang, W. & Zhang, D. Y. Anticancer activity of Scutellaria baicalensis and its potential mechanism. J. Altern. Complement. Med. 8, 567–572 (2002).
Sovak, M. et al. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J. Natl Cancer Inst. 94, 1275–1281 (2002). A detailed and scientific delineation of the adulterants in PC-SPES and their variation with patterns of use of the mixture.
Mills, P. K., Beeson, W. L., Phillips, R. L. & Fraser, G. E. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64, 598–604 (1989).
Giovannucci, E., Rimm, E. B., Liu, Y., Stampfer, M. J. & Willett, W. C. A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl Cancer Inst. 94, 391–398 (2002).
Giovannucci, E. et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl Cancer Inst. 87, 1767–1776 (1995).
Cohen, J. H., Kristal, A. R. & Stanford, J. L. Fruit and vegetable intakes and prostate cancer risk. J. Natl Cancer Inst. 92, 61–68 (2000).
Bohm, F., Tinkler, J. H. & Truscott, T. G. Carotenoids protect against cell membrane damage by the nitrogen dioxide radical. Nature Med. 1, 98–99 (1995).
Di Mascio, P., Kaiser, S. & Sies, H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem. Biophys. 274, 532–538 (1989).
Nahum, A. et al. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 20, 3428–3436 (2001).
Guttenplan, J. B. et al. Effects of a lycopene-rich diet on spontaneous and benzo[a]pyrene-induced mutagenesis in prostate, colon and lungs of the lacZ mouse. Cancer Lett. 164, 1–6 (2001).
Chen, L. et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J. Natl Cancer Inst. 93, 1872–1879 (2001). A prospective study of the preoperative use of tomato products showed that markers of oxidant damage in prostate, prostate cancer and peripheral blood were significantly reduced with tomato products that contained high levels of lycopene.
Kucuk, O. et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. 10, 861–868 (2001).
Marks, L. S. et al. PC-SPES: herbal formulation for prostate cancer. Urology 60, 369–375 (2002).
Pandha, H. S. & Kirby, R. S. PC-SPES: phytotherapy for prostate cancer. Lancet 359, 2213–2215 (2002).
Chenn, S. In vitro mechanism of PC SPES. Urology 58, 28–35 (2001).
Gerber, G. S. Saw palmetto for the treatment of men with lower urinary tract symptoms. J. Urol. 163, 1408–1412 (2000).
Wilt, T. J. et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 280, 1604–1609 (1998).
Goldmann, W. H. et al. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol. Int. 25, 1117–1124 (2001).
DiPaola, R. S. et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N. Engl. J. Med. 339, 785–791 (1998).
de la Taille, A. et al. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J. Urol. 164, 1229–1234 (2000).
Small, E. J. et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J. Clin. Oncol. 18, 3595–3603 (2000).
Small, E. J. et al. A prospective multicenter randomized trial of the herbal supplement, PC-SPES vs. diethylstilbestrol (DES) in patients with advanced, androgen independent prostate cancer (AiPCa). Am. Soc. Clin. Oncol. A709 (2002).
White, J. PC-SPES: a lesson for future dietary supplement research. J. Natl Cancer Inst. 94, 1261–1263 (2002).
Weinrobe, M. C. & Montgomery, B. Acquired bleeding diathesis in a patient taking PC-SPES. N. Engl. J. Med. 345, 1213–1214 (2001).
Feifer, A. H., Fleshner, N. E. & Klotz, L. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J. Urol. 168, 150–154 (2002).
Chan, T. Y., Chan, J. C., Tomlinson, B. & Critchley, J. A. Chinese herbal medicines revisited: a Hong Kong perspective. Lancet 342, 1532–1534 (1993).
Huang, W. F., Wen, K. C. & Hsiao, M. L. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J. Clin. Pharmacol. 37, 344–350 (1997).
Ko, R. J. Adulterants in Asian patent medicines. N. Engl. J. Med. 339, 847 (1998).
Mansky, P. J. & Straus, S. E. St. John's Wort: more implications for cancer patients. J. Natl Cancer Inst. 94, 1187–1188 (2002).
Cassileth, B. & Lucarelli, C. Herb–Drug Interactions in Oncology (B. C. Decker, Hamilton, 2003).
Bonham, M. J. et al. Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J. Natl Cancer Inst. 94, 1641–1647 (2002). This study shows that PC-SPES has effects on microtubule dynamics in prostate cancer that are independent of potential DES contamination and that antagonize the effect of microtubule-stabilizing agents, implying that PC-SPES might antagonize chemotherapy for advanced disease.
Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N. Engl. J. Med. 349, 366–381 (2003).
Hayes, R. B. et al. Sexual behaviour, STDs and risks for prostate cancer. Br. J. Cancer 82, 718–725 (2000).
Habel, L. A., Zhao, W. & Stanford, J. L. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13, 427–434 (2002).
De Marzo, A. M., Marchi, V. L., Epstein, J. I. & Nelson, W. G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155, 1985–1992 (1999).
World Cancer Research Fund and American Institute for Cancer Research. Food, nutrition, and the prevention of cancer: a global perspective. (American Institute for Cancer Research, Washington DC, 1997).
Kolonel, L. N., Hankin, J. H. & Yoshizawa, C. N. Vitamin A and prostate cancer in elderly men: enhancement of risk. Cancer Res. 47, 2982–2985 (1987).
Gann, P. H. et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 5, 121–126 (1996).
Chan, J. M. et al. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am. J. Clin. Nutr. 74, 549–554 (2001).
West, D. W., Slattery, M. L., Robison, L. M., French, T. K. & Mahoney, A. W. Adult dietary intake and prostate cancer risk in Utah: a case–control study with special emphasis on aggressive tumors. Cancer Causes Control 2, 85–94 (1991).
Yoshizawa, K. et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Natl Cancer Inst. 90, 1219–1224 (1998).
Key, T. J., Silcocks, P. B., Davey, G. K., Appleby, P. N. & Bishop, D. T. A case–control study of diet and prostate cancer. Br. J. Cancer 76, 678–687 (1997).
Oishi, K. et al. A case–control study of prostatic cancer with reference to dietary habits. Prostate 12, 179–190 (1988).
Jain, M. G., Hislop, G. T., Howe, G. R. & Ghadirian, P. Plant foods, antioxidants, and prostate cancer risk: findings from case–control studies in Canada. Nutr. Cancer 34, 173–184 (1999).
Hebert, J. R. et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J. Natl Cancer Inst. 90, 1637–1647 (1998).
Ellison, L. F. Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. Eur. J. Cancer Prev. 9, 125–130 (2000).
Poisson, B. A. et al. Pharmacokinetic analysis of the putative prostate cancer chemopreventive agent, genistein. Proc.Am. Soc. Clin. Oncol. A334 (2001).
Hennekens, C. H. et al. Lack of effect of long-term supplementation with β carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334, 1145–1149 (1996).
The authors thank the Association for the Cure of Cancer of the Prostate (CaPURE) for support. Peter Nelson is supported by a Scholar Award from the Damon Runyan Cancer Research Foundation.
- TOCOPHEROLS AND TOCOTRIENOLS
Tocopherols are substituted benzopyranols (methyl tocols) that occur in vegetable oils. Different forms (α, β, γ and δ) are recognized according to the number or position of methyl groups on the aromatic ring. α-tocopherol is an important natural antioxidant. Tocotrienols have similar ring structures as tocopherols, but have three double bonds in the aliphatic chain.
Chemicals that contain more than one aromatic phenol ring.
Chemicals that are derived from plant sources which have oestrogen-like effects on animal tissues or cell lines.
Proteolytic enzymes that break down the extracellular matrix.
- TRAMP MICE
(Transgenic adenocarcinoma of the mouse prostate). A transgenic mouse strain in which the oncogenic SV40 T antigen is expressed in prostate tissue. Animals spontaneously develop preneoplastic lesions and malignancy of the prostate and the model has been used to study methods to prevent and treat prostate cancer in vivo.
(Prostate-specific antigen). A member of the kallikrein family that is made by normal and malignant prostate tissues and that can be secreted into the blood. Detection of PSA from blood tests is one way of detecting and following prostate cancer.
A class of hormone-like substances that are formed in the body from long-chain essential fatty acids.
- SCID MICE
Mice that are homozygous for the SCID mutation have compromised B- and T-cell immunity. This lack of immunity means that they can support human tumour xenografts for preclinical studies.
Any group of pigments, yellow to deep red in colour, chemically consisting of polyisoprene hydrocarbons. Carotenoids are synthesized by higher plants and concentrate in animal fat when eaten.
- REACTIVE OXYGEN SPECIES
The chemical reactions and physical changes involving molecular oxygen (O2), or any of the reactive oxygen species such as superoxide anions (O2−), hydrogen peroxide (H2O2) and hydroxyl radicals (–OH).
A mixture of oil and resin that occurs naturally in certain plant tissues, and that can be extracted.
A small berry-shaped fruit that grows on the Saw palmetto palm tree (known as sabal in Europe). Saw palmetto grows naturally in the southeast United States (for example, in Georgia, Mississippi and Florida) and has been used for thousands of years by the Native Americans to treat urinary problems.
- HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
A method that is used to separate molecules through the use of high-pressure application of complex solutions to matrices that preferentially bind or exclude species depending on the matrix and the compound of interest.
About this article
Cite this article
Nelson, P., Montgomery, B. Unconventional therapy for prostate cancer: good, bad or questionable?. Nat Rev Cancer 3, 845–858 (2003). https://doi.org/10.1038/nrc1210
Current Drug Therapy (2019)
Hydroalcoholic extract of the widely used Mexican plant Justicia spicigera Schltdl. exerts a cytostatic effect on LNCaP prostate cancer cells
Journal of Herbal Medicine (2018)
Pharmacological evidences for cytotoxic and antitumor properties of Boswellic acids from Boswellia serrata
Journal of Ethnopharmacology (2016)
The andean anticancer herbal product BIRM causes destabilization of androgen receptor and induces caspase-8 mediated-apoptosis in prostate cancer
Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma
Journal of Hematology & Oncology (2015)